ServiziMenu principaleHome
You are here:  > Educational Opportunities > Past events > 2011 > Educational Cancer Convention Lugano - What's New and What's True in Genito-Urinary Oncology?
Share on Share on Facebook Twitter Share on Linkedin Share on WhatsApp Share on Instagram Share by email Print this page

Educational Cancer Convention Lugano - What's New and What's True in Genito-Urinary Oncology?

12 ESCO credits

12.05.2011  -  14.05.2011

Lugano, Switzerland


Genito-urinary cancers


Chair: D. Berthold, CH and B. Tombal, BE

On behalf of ESO and of the Scientific Committee, we have the pleasure of inviting you to attend the Educational Cancer Convention Lugano.

The 2011 edition will be devoted to genito-urinary oncology with a programme developed with special attention the multidisciplinary care of patients with prostate, bladder, renal and testicular cancer. The program should be equally interesting for urologists, radiation and medical oncologists as well as clinicians in training in those specialities. The programme includes state of the art lectures, controversies and gives ample time for discussion of abstracts and clinical cases provided by the participants.

We look forward to welcome you to ECCLU 2011 and to your active participation.

Dominik Berthold and Bertrand Tombal
Course Chairmen

ECCLU is part of the Sharing Progress in Cancer Care programme whose sustaining members are:
Platinum members: Amgen and Eisai
Gold members: Eli Lilly, GlaxoSmithKline Oncology and Merck Serono
Silver member: Genomic Health, Novartis Oncology and Sanofi-Aventis

General information


European School of Oncology 
ESO Bellinzona Office
Ospedale Regionale
6500 Bellinzona, Switzerland
Tel:  +41 91 811 8050
Fax: +41 91 811 8051

Programme and organisation
Chatrina Melcher - ESO Bellinzona (
Abstracts and programme
Dolores Knupfer - ESO Bellinzona (
Laura Richetti (


By 15 February 2011      Abstract submission
By 21 February 2011    Early registration
By 6 May 2011         Late registration

Palazzo dei Congressi,
Lugano, Switzerland
Lugano is reachable by plane via Zurich (45-minute flight or 2,5-hour train) or from Milano Malpensa airport (2-hour drive, shuttle service).

How to reach Lugano:

AirplaneLugano-Agno Airport (LUG) is located at 6 km from the town and it is the ideal point of arrival. A shuttle service to/from the centre and hotels is available. Please visit http://www.shuttle-bus.com/ for further information.
TrainFast and easy connections by train are available to Zurich (3 hours) or to Milan Central Station (not airport!).

Milano Malpensa

The transfer from the Milano Malpensa airport to Lugano takes approximately 1 hour and 15 minutes. Please note that booking is required. More information on schedule, duration, cost and booking form for the transfer are available at http://www.malpensaexpress.ch or www.starstation.ch.

The organisers bear no responsibility for untoward events in relation with the participation in the Convention. Participants are advised to take out their own personal and travel insurance coverage.

All participants will be issued a certificate of attendance at the close of the Convention.
ECCLU has been appraised and approved by the Accreditation Council of Oncology in Europe (ACOE) acknowledging the quality of the scientific programme and its educational value.
ACOE is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS). The “Educational Cancer Convention Lugano – ECCLU: What’s New and What’s True in Genito-urinary Oncology” is designated for a maximum of 14 hours of European external CME credits. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity. EACCME credits are recognised by the American Medical Association towards the Physician’s Recognition Award (PRA). To convert EACCME credit to AMA PRA category 1 credit, the participant should contact the AMA.
The programme is furthermore accredited with 18 ESMO-MORA category 1 points.

ESO is grateful to the City of Lugano for their interest and continuous support in the organisation of ECCLU and to the European Society for Medical Oncology for their co-operation and support of travel grants.

A limited number of travel grants are assigned on a competitive basis from among participants from middle-low income countries who have had an abstract accepted for oral or for poster presentation.
The curriculum vitae should be submitted at the same time as the abstract (deadline: 15 February) indicating the amount requested to cover economy fare. Successful applicants will be granted registration, accommodation for 2 nights and refund of actual travel costs (flight only) on site at the end of the Convention.

The official language of the Convention will be English. No translation will be provided.

The abstract book will be published as a supplement to the Critical Reviews in Oncology/Hematology and will contain abstracts of the invited lectures and those submitted by the participants that have been accepted for oral or poster presentation.

Faculty list

J.J. Battermann, University Medical Centre Utrecht, Dept. of Radiotherapy, Utrecht, NL
J. Bellmunt, Hospital del Mar, Medical Oncology Service, Barcelona, ES
D. Berthold, University Hospital Canton Vaud, Pluridisciplinary Centre for Oncology, Lausanne, CH
A. Bex, The Netherlands Cancer Institute, Antoni van Leeuwenhoek Hos, Department of Urology, Amsterdam, NL
M. Bolla, University Hospital of Grenoble - La Tronche, Department of Radiotherapy, Grenoble FR
C. Bosetti, Mario Negri Institute for Pharmacological Research, Department of Epidemiology, Milan, IT
N. Clarke, Christie Hospital and Salford Royal Hospitals NHS Trusts, Department of Urological Oncology, Manchester, UK
A. Costa, European School of Oncology, Scientific Director, Bellinzona CH and Milan, IT
Z. Culig, Innsbruck Medical University, Department of Urology, Innsbruck, AT
M. De Santis, Kaiser Franz Josef Hospital - SMZ Süd, Center for Oncology and Hematology, Vienna, AT
V. Ficarra, University of Padua, Urologic Clinic, Department of Oncologic and Surgical Sciences, Padova, IT
K. Fizazi, Institut Gustave Roussy, Department of Cancer Medicine, Villejuif, FR
V. Griesser, Europa Uomo Switzerland, Châtel-St-Denis, CH
A. Horwich, The Royal Marsden Hospital, Department of Radiotherapy, Sutton, UK
N. James, University of Birmingham, CRUK Institute for Cancer Studies, Birmingham, UK
F.J. Murat, Val d'Ouest Hospital, Department of Urology, Ecully, FR
Ch. Parker, The Royal Marsden NHS Foundation Trust, Academic Urology Unit, Sutton, UK
B.I. Rini, Cleveland Clinic Taussig Cancer Institute, Department of Solid Tumor Oncology, Cleveland, US
Ch. Rothermundt, Cantonal Hospital St. Gallen, Department of Oncology, St. Gallen, CH
S. Supiot, Centre René-Gauducheau, Department of Radiotherapy, Nantes-St-Herblain, FR
I. Tannock, Princess Margaret Hospital - University of Toronto, Department of Oncology and Hematology, Toronto, CA
G. Thalmann, University of Berne, Inselspital, Department of Urology, Berne, CH
B. Tombal, Cliniques Universitaires Saint-Luc, Department of Urology, Brussels, BE
H. Van Poppel, U.Z. Gasthuisberg, Department of Urology, Leuven, BE
A. Widmark, Umea University Hospital, Department of Radiation Sciences - Oncology, Umea, SE
Th. Wiegel, University Hospital Ulm, Department of Radiation Oncology, Ulm, DE



12 May


D. Berthold, CH – A. Costa, IT/CH

 11:00Epidemiology in Europe
C. Bosetti, IT

Localised invasive bladder cancer
Chair: A. Bex, NL
Neo-adjuvant chemotherapy
         J. Bellmunt, ES
Surgery           G. Thalmann, CH
12:05 Radiotherapy           N. James, UK


Palliative chemotherapy
M. De Santis, AT

 13.00Lunch and poster session

Oral abstract presentations
Chair: I. Tannock, CA
14:00 Ex-vivo ultrasound control of resection margins during partial nephrectomy (Abstract 25)        Y. Cerantola, CH
14:10 Reasonability of lymph dissection in localized types of renal cell carcinoma (Abstract 26)        N. Rahimov, UZ
14:20 Quality of life in metastatic renal cell carcinoma patients with ECOG PS >2 receiving             targeted therapy (Abstract 27)        I. Tsimafeyeu, RU
14:30 Choosing the extent of the lymph node dissection in surgical treatment of the bladder cancer               with regional metastasis (Abstract 28)         E. Kolesnikova, UZ


Mechanisms of action in modern RCC treatment  
(Lecture sponsored by Novartis Oncology)
Ch. Rothermundt, CH

 15:15Coffee break


Kidney cancer 
Chair: G. Thalmann, CH
(The session will be webcast as part of the e-grandround programme www.e-eso.net
First and further lines in mRCC
         B.I. Rini, US
Adjuvant and neo-adjuvant treatment
         A. Bex, NL
Non-clear cell histology
         J. Bellmunt, ES
Surgery (including nephron-sparing surgery)
         H. Van Poppel, BE


Keynote lecture: New developments in the systemic treatment of advanced prostate cancer
I. Tannock, CA
(The lecture will be webcast as part of the e-grandround programme


Welcome cocktail 


13 May


Prostate cancer: From biology to live expectancy
Chair: Ch. Parker, UK
         Z. Culig, AT
Screening and active surveillance
         B. Tombal, BE


Coffee break


Prostate cancer: All the truth about local treatment options T1-T2
Chair: B. Tombal, BE
         A. Widmark, SE
         V. Ficarra, IT
         J.J. Battermann, NL
12:00 High-intensity focused ultrasound and cryotherapy        F.J. Murat, FR


Oral abstract presentations /Case reports 
Chair: D. Berthold, CH

12:20 On the role of magnetic resonance imaging with Endorectal Coil (ER-MRI)             in changing the stage (and    treatment approach) in patients with early             prostate cancer undergoing primary radiation (Abstract 29)         M. Romano, IT
12:30 Weight change analysis in advanced castration resistant prostate cancer            (CRPC) patients treated with Abiraterone Acetate (AA) single agent and in             combination with steroids (Abstract 30)        D. Bianchini, UK
12:40 Evaluating the antitumour activity of docetaxel following treatment with               abiraterone acetate and steroids: Evidence for cross-resistance         (Abstract 31)        J. Mezynski, UK
12:50 Current status of prostate cancer in Lagos, Nigeria (Abstract 32)        O. Adetayo, NG


Lunch and poster session


Controversy: Locally advanced prostate cancerModerator: B. Tombal, BE
Pro surgery
         H. Van Poppel, BE
Pro radiation
         Ch. Parker, UK
14:40 Discussion and conclusion         B. Tombal, BE


Locally advanced prostate cancer: Multimodality treatment and new drugs combined with radiotherapy
S. Supiot, FR


Coffee break


Prostate cancer: Locally advanced disease and patient advocacy
Chair: D. Berthold, CH
16:00 Europa Uomo: The patients’ voice
         V. Griesser, CH

Adjuvant versus salvage radiation
         M. Bolla, FR
Integrating systemic therapy into high-risk disease
         K. Fizazi, FR


Prostate cancer: Managing of pelvic nodes
Chair: B. Tombal, BE
17:30 Surgical perspective        H. Van Poppel, BE
18:00 Radiation perspective         Th. Wiegel, DE


14 May


Prostate cancer drug development
K. Fizazi, FR


Side-effects of anti-androgen therapy
B. Tombal, BE
 10:30Coffee break


Bone targeted agents
N. Clarke, UK


Testicular cancer
N. Clarke, UK
11:30 Options in stage I testicular cancer
         A. Horwich, UK
12:00 Treatment of advanced testicular cancer
         K. Fizazi, FR
12:30 Role of surgery in the management of testis cancer 
         N. Clarke, UK


Closing remarks

Pure red cell dysplasia in a patient with metastatic cancer prostate
(Abstract 33)
R.A. Malek, EG
Role of immunehistochemical markers in definition of hormone sensation prostate cancer  
(Abstract 34)
E. Kolesnikova, UZ

Intermittent hormonal therapy in the treatment of prostate cancer
(Abstract 35)
N. Rahimov, UZ

Dural metastases from prostatic adenocarcinoma: Case report and review of literature  
(Abstract 36)
A. Salem, JO

Multiple successive surgery and chemotherapy helped to dramatically prolong life in patient with bladder cancer  
(Abstract 37)
E. Shakhnovich, RU

Cytoreductive nephrectomy in advanced or metastasis renal cell carcinoma: In the era of targeted strategies  
(Abstract 38)
C. Toutziaris, GR

Supraclavicular lymphadenopathy as the initial clinical symptom of a rare histological type of renal cancer 
(Abstract 39)
C. Toutziaris, GR

Atypical initial clinical presentation of a prostate cancer
with normal PSA
(Abstract 40)
C. Toutziaris, GR


The deadline to submit abstracts is passed (15 February 2011).

Participants are invited to submit an abstract on basic research, clinical study or a clinical case in genito-urinary oncology, in one of the following categories:

  • Bladder cancer
  • Kidney cancer
  • Prostate cancer
  • Testicular cancer

Abstracts on basic research will be considered for poster presentation only.
Abstracts on clinical cases or clinical studies will be considered for oral presentation or poster presentation.

Participants submitting abstracts on a clinical case are encouraged to describe frequent disorders, where a clinical-therapeutic decision making is controversial.
The oral presentation of clinical cases will be scheduled with a 5-minute presentation (maximum of 5 slides) followed by a 5-minute discussion.

Accepted abstracts will be published in the ECCLU 2011 Abstract Book, supplement to the Critical Reviews in Oncology/Hematology.


  • The abstract should be limited to 2000 characters, including the title.
  • The title should  be in lower case letters.
  • Each author should be listed with First Name, followed by Family Name.
  • The first author should be underlined (first author = corresponding author and presenter).
  • List affiliations after the authors’ list.
  • The full address with e-mail address, phone and fax numbers of the first author (+ corresponding author and presenter) must be provided. The first author will receive an acknowledgement of receipt and all subsequent communication by e-mail.
  • For abstracts accepted for presentation, the first author will be the presenting author and is requested to register and participate in the Convention.
  • It is the responsibility of the first author to ascertain whether all authors are aware of the content of the abstract before submission is made.

The acknowledgement of receipt of the abstract will immediately follow the submission. The outcome will be notified by the end of February to the first author who will be required to register to the Convention.